A public-private partnership known as CARB-X plans to devote more than $350 million over five years “to one of the trickiest aspects of the problem of drug resistance: Encouraging pharmaceutical companies to make new antibiotics,” says National Geographic. Antibiotics are expensive to develop but often a low-revenue product, so there is little research at a… » Read More